Pharmacology  ·  General Anesthesia

Principles of General Anesthesia

Inhalational pharmacokinetics, anesthetic potency, intravenous agents, and preanesthetic medications


Abbreviations: MAC = minimum alveolar concentration  ·  IV = intravenous  ·  QT = QT interval on the electrocardiogram

Key Pharmacokinetic Property

Blood:Gas Partition Coefficients and Induction Speed

Agent Blood:Gas Coefficient Induction Speed Clinical Notes
Desflurane ~0.42 (lowest) Fastest Pungent — not used for inhalational induction; very rapid emergence
Nitrous oxide ~0.47 Very fast Minimum alveolar concentration 104% — cannot produce surgical anesthesia alone
Sevoflurane ~0.65 Fast Preferred agent for pediatric inhalational induction; pleasant odor
Isoflurane ~1.4 Moderate Standard volatile agent for maintenance; pungent odor limits inhalational induction
Halothane ~2.4 (highest) Slowest High hepatotoxicity risk — largely replaced by newer agents

Rule: Low blood:gas coefficient = low solubility in blood = fast rise in alveolar partial pressure = fast induction. High coefficient = slow induction, slow emergence.

Minimum Alveolar Concentration

Factors That Decrease MAC

  • Advanced age (most clinically significant)
  • Hypothermia
  • Opioids
  • Benzodiazepines
  • Alpha-2 agonists (dexmedetomidine, clonidine)
  • Acute alcohol intoxication
  • Pregnancy

Minimum Alveolar Concentration

Factors That Increase MAC

  • Hyperthermia
  • Chronic alcohol use
  • Hypernatremia
  • Pediatric age (children have higher minimum alveolar concentration than adults)

MAC additivity: 0.5 minimum alveolar concentration isoflurane + 0.5 minimum alveolar concentration nitrous oxide = 1.0 minimum alveolar concentration effect. MAC-awake (return of consciousness) = approximately 0.3–0.4 minimum alveolar concentration.

IV Induction Agent

Propofol

  • Mechanism: gamma-aminobutyric acid type A potentiation
  • Most widely used induction agent; antiemetic properties
  • Propofol infusion syndrome: metabolic acidosis, rhabdomyolysis, cardiac failure — prolonged high-dose infusion; avoid in pediatric intensive care

IV Induction Agent

Etomidate

  • Mechanism: gamma-aminobutyric acid type A potentiation
  • Minimal cardiovascular effects — preferred in hemodynamic instability
  • Adrenocortical suppression: inhibits 11-beta-hydroxylase; blocks cortisol for 6–24 hours after single dose

IV Induction Agent

Ketamine

  • Mechanism: N-methyl-D-aspartate receptor antagonism → dissociative anesthesia
  • Sympathomimetic: increases heart rate, blood pressure, cardiac output
  • Potent bronchodilator
  • Increases intracranial pressure — caution in head injury
  • Emergence reactions: hallucinations, dysphoria — mitigated by benzodiazepine

IV Sedation Agent

Dexmedetomidine

  • Mechanism: alpha-2 adrenergic agonist (locus coeruleus)
  • Sedation without respiratory depression
  • Arousable, cooperative patients — ideal for procedural sedation and intensive care sedation
  • Adverse effects: bradycardia, hypotension

Drug Classes and Mechanisms

Preanesthetic Medication Summary

Drug Mechanism Primary Use Key Point
Midazolam Gamma-aminobutyric acid type A potentiation Anxiolysis, anterograde amnesia, reduces minimum alveolar concentration Most widely used preanesthetic sedative
Fentanyl Opioid receptor agonist Baseline analgesia; blunts laryngoscopy hemodynamic response Rapid onset IV; risk of respiratory depression
Ondansetron 5-hydroxytryptamine type 3 antagonist Postoperative nausea and vomiting prophylaxis Given at end of surgery for early nausea and vomiting
Dexamethasone Glucocorticoid Postoperative nausea and vomiting prophylaxis Given at induction (delayed onset)
Droperidol Dopamine D2 antagonist Postoperative nausea and vomiting prophylaxis Black box warning: QT prolongation / torsades de pointes
Glycopyrrolate Muscarinic antagonist (quaternary amine) Antisialagogue; does not cross blood-brain barrier No central anticholinergic effects (compare atropine)
Metoclopramide Dopamine D2 antagonist + 5-hydroxytryptamine type 4 agonist Aspiration prophylaxis: empties stomach, increases lower esophageal sphincter tone Contraindicated in bowel obstruction
Sodium citrate Non-particulate antacid (direct buffer) Rapid neutralization of gastric acid before induction Safe if aspirated (non-particulate)

Suggested References

Author / OrganizationTitleSource
Katzung BG, ed.Basic and Clinical Pharmacology. 15th ed.McGraw-Hill; 2021
Brunton LL, Knollmann BC, eds.Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed.McGraw-Hill; 2023
Eger EI 2ndAnesthetic Uptake and ActionBaltimore: Williams & Wilkins; 1974
Miller RD, ed.Miller's Anesthesia, 8th ed. Chapters 17, 27Philadelphia: Elsevier; 2015
Malviya S, Lerman JThe blood/gas solubilities of sevoflurane, isoflurane, halothane, and serum constituent concentrations in newborns and adultsAnesthesiology. 1990;72(5):793–796
Stoelting RK, Hillier SCPharmacology and Physiology in Anesthetic Practice, 4th ed.Philadelphia: Lippincott Williams & Wilkins; 2006
Apfel CC, et al.A simplified risk score for predicting postoperative nausea and vomitingAnesthesiology. 1999;91(3):693–700
Eger EI 2ndAge, minimum alveolar anesthetic concentration, and minimum alveolar anesthetic concentration-awakeAnesth Analg. 2001;93(4):947–953
Fink BRDiffusion anoxiaAnesthesiology. 1955;16(4):511–519
Epstein RM, et al.Influence of the concentration effect on the uptake of anesthetic mixtures: the second gas effectAnesthesiology. 1964;25:364–371
Eger EI 2nd, Saidman LJ, Brandstater BMinimum alveolar anesthetic concentration: a standard of anesthetic potencyAnesthesiology. 1965;26:756–763
Gan TJ, et al.Consensus guidelines for the management of postoperative nausea and vomitingAnesth Analg. 2014;118(1):85–113
Flood P, Rathmell JP, Shafer SL, eds.Stoelting's Pharmacology and Physiology in Anesthetic Practice, 5th ed.Philadelphia: Wolters Kluwer; 2015
Marik PEPropofol: therapeutic indications and side-effectsCurr Pharm Des. 2004;10(29):3639–3649
White PF, et al.Pharmacology of ketamine isomers in surgical patientsAnesthesiology. 1980;52(3):231–239
Weerink MAS, et al.Clinical pharmacokinetics and pharmacodynamics of dexmedetomidineClin Pharmacokinet. 2017;56(8):893–913